Biotechnology company Sinopia Biosciences, Inc. has entered into a research collaboration with Japanese pharmaceutical firm Ono Pharmaceutical Co., Ltd. to discover new therapeutic targets for a group of rare metabolic disorders that currently lack effective treatments. The partnership will leverage Sinopia’s proprietary drug discovery technologies to uncover novel biological pathways that could lead to future medicines for patients affected by these conditions.
The collaboration will focus on identifying and validating targets associated with an undisclosed set of genetically defined metabolic diseases that represent significant unmet medical needs. As part of the agreement, Sinopia will utilize its LEADS® (LEarn And DiScover) discovery platform, which integrates metabolomics data with computational biology approaches to uncover potential disease mechanisms and therapeutic opportunities.
Metabolic disorders often arise from disruptions in biochemical pathways that regulate essential processes such as energy production, nutrient metabolism, or cellular signaling. Because many rare metabolic diseases are linked to genetic mutations affecting these pathways, identifying the underlying biological targets is considered a critical step in developing effective treatments.
Sinopia’s platform is designed to analyze metabolic signatures within cells and tissues to pinpoint the biochemical dysfunction driving disease progression. By combining metabolomics insights with advanced computational modeling and machine learning techniques, the company aims to reveal previously unrecognized therapeutic targets.
Under the terms of the collaboration, Sinopia will lead the target discovery and validation work using its technology platform. Once promising targets are identified, Ono Pharmaceutical will have the option to advance those discoveries into drug development programs aimed at creating new therapies for patients.
Financial details of the agreement were not disclosed. However, Sinopia will receive research funding and an upfront payment from Ono Pharmaceutical and may also earn additional milestone payments tied to the progress of the collaboration.
Iman Famili, chief executive officer of Sinopia Biosciences, said the partnership highlights the growing value of metabolomics-driven drug discovery in tackling complex genetic diseases. According to Famili, the company’s LEADS platform provides a powerful approach for uncovering new therapeutic opportunities in rare metabolic disorders where treatment options remain limited.
He noted that working with Ono Pharmaceutical could significantly expand the reach of Sinopia’s discovery capabilities and accelerate the development of therapies for patients and families affected by these conditions.
The collaboration also reflects a broader trend in the biotechnology industry toward integrating computational biology, artificial intelligence, and large-scale biological data to improve target discovery. By applying these advanced tools, companies hope to identify disease mechanisms more efficiently and increase the chances of developing successful therapies.
For Ono Pharmaceutical, the agreement provides access to Sinopia’s specialized metabolomics expertise and discovery platform, which could help broaden the company’s research pipeline in rare diseases. For Sinopia, the partnership serves as further validation of its technology and supports its long-term mission of developing transformative medicines using data-driven biological insights.
If successful, the collaboration could pave the way for the development of new treatments addressing the root causes of rare metabolic diseases, offering hope to patients who currently have few therapeutic options.